| (USD) | Mar 2024 | Q/Q |
|---|---|---|
| Revenue | 2.4B | +3% |
| Gross Profit | 771MM | - |
| Cost Of Revenue | 1.6B | +3% |
| Operating Income | 300MM | +12% |
| Operating Expenses | 471MM | - |
| Net Income | 194MM | +1% |
| G&A | 440MM | +8% |
| Amortization | 29MM | +7% |
| Interest Expense | 49MM | +7% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2024 Earnings Call Transcript April 23, 2024 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $2.04, expectations were $1.86. DGX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Quest Diagnostics First […]
Let's talk about the popular Quest Diagnostics Incorporated ( NYSE:DGX ). The company's shares saw a decent share price...
Quest Diagnostics ( NYSE:DGX ) First Quarter 2024 Results Key Financial Results Revenue: US$2.37b (up 1.5% from 1Q...
Discover the pivotal financial results and strategic insights from Quest Diagnostics' first quarter of 2024, including revenue growth, EPS guidance, and operational achievements.
Q1 2024 Quest Diagnostics Inc Earnings Call
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
Comprehensive Analysis of Quest Diagnostics' Latest Financial Performance
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 9.68% and 3.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2024.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Quest Diagnostics (DGX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.